The Harth Lab is developing novel biomedical materials and technologies to increase the therapeutic function of synthetic and biological substances.
We develop novel methods to create polymeric networks also in nanoscale to control the interaction of therapeutics and activators with tissues, cells and barriers.
Furthermore, organic and polymer chemistry is allowing for the precise synthesis and reactions of macromolecular building blocks to form a host of materials that can be tuned to serve in diverse biomedical applications.
Developed 3-D nano networks, “nanosponges” can be tailored in their size, linear release profile of drugs and are easily functionalized with targeting, labeling and cell penetrating units. Hydrophobic drug molecules can be incorporated in a postloading procedure, allowing for single and multi-drug incorporation. The resulting particles are well dispersed in aqueous solutions for in vitro and in vivo applications.
These properties and features of the delivery system have contributed to enhance drug solubilization, increased efficacy in models of lung, brain and breast cancer and in eye diseases such as glaucoma. The delivery system is further investigated in the targeting of islet cells and in the treatment of diabetes and in the development of hybrid-combination treatments.
Polyglycidol macromolecules are optimized and to work in bioconjugates and composite materials. Delivery materials that enable the synergistic therapeutic effect of proteins and synthetic molecules are developed in novel hydrogel materials and particles to develop the next generation of delivery devices.